实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (5): 689-692.doi: 10.3969/j.issn.1672-5069.2026.05.013

• 药物性肝损伤 • 上一篇    下一篇

113例药物性肝损伤患者临床表现、肝组织病理学特征和预后分析*

高鹏, 罗淼, 刘赟   

  1. 473000 河南省南阳市中心医院病理科(高鹏);普通外科(刘赟);郑州大学附属肿瘤医院内窥镜诊断治疗中心(罗淼)
  • 收稿日期:2025-11-17 发布日期:2026-09-14
  • 作者简介:高鹏,男,46岁,大学本科,主管技师。E-mail:gpnasa@126.com
  • 基金资助:
    河南省科技厅医学科技攻关计划项目(编号:LHGJ20220814)

Clinical and pathological features of patients with drug-induced liver injury: An analysis of 113 cases

Gao Peng, Luo Miao, Liu Yun   

  1. Department of Pathology, Central Hospital,Nanyang 473000,Henan Province,China
  • Received:2025-11-17 Published:2026-09-14

摘要: 目的 分析总结药物性肝损伤(DILI)患者的临床表现、肝组织病理学特征和预后情况。方法 2022年1月~2024年12月我院收治的113例DILI患者,接受肝活检行组织病理学检查,常规临床检测行临床分型和病情分级。停止可疑药物,给予积极的护肝处理。结果 在113例DILI患者中,肝细胞损伤型58例(51.3%),胆汁淤积型20例(17.7%),和混合型35例(31.0%);混合型出现黄疸占比为71.4%,显著高于胆汁淤积型的55.0%(P<0.05),混合型和胆汁淤积型≥3级病情占比分别为54.2%和55.0%,显著高于肝细胞损伤型的34.5%(P<0.05);混合型和胆汁淤积型血清总胆红素水平分别为(55.2±12.8)μmol/L和(59.7±14.2)μmol/L,均显著高于肝细胞损伤型【(23.5±11.6)μmol/L,P<0.05】,INR分别为(1.5±0.2)和(1.3±0.2),均显著大于肝细胞损伤型【(1.0±0.2),P<0.05】;肝细胞损伤型患者肝组织以肝细胞气球样变性和点灶状坏死为主,胆汁淤积型患者肝组织以胆汁淤积和胆管损伤为主,而混合型则兼具以上两型的组织学损伤;经1~3周治疗,肝细胞损伤型患者痊愈55例(94.8%),胆汁淤积型痊愈15例(75.0%),混合型痊愈28例(80.0%)。结论 DILI 患者临床表现不具备明显的特异性,最常见的损伤类型为肝细胞损伤型。停用可疑药物,及时给予护肝治疗,大多预后良好。

关键词: 药物性肝损伤, 临床特征, 病理学特征, 预后

Abstract: Objective The aim of this study was to summarize clinical and pathological features of a series of patients with drug-induced liver injury (DILI). Methods 113 patients with DILI were encountered in our hospital between January 2022 and December 2024, and all patients underwent liver biopsies. Types and degrees of liver injury were classified based on clinical materials. Results Of the 113 patients with DILI, there were 58 cases (51.3%) with hepatocyte injury type, 20 cases (17.7%) with cholestasis type and 35 cases (31.0%) with mixed type; proportion of jaundice in patients with mixed was 71.4%,much higher than 55.0%(P<0.05) in those with and cholestasis types, proportions of ≥class 3 liver injury in patients with mixed and cholestasis types were 54.2% and 55.0%,both much higher than 34.5%(P<0.05) in those with hepatocyte injury; serum total bilirubin levels in patients with mixed and cholestasis types were(55.2±12.8)μmol/L and (59.7±14.2)μmol/L, both significantly higher than [(23.5±11.6)μmol/L,P<0.05],and INR were (1.5±0.2) and (1.3±0.2), both much greater than [(1.0±0.2),P<0.05] in those with hepatocyte injury; in terms of pathological manifestations, patients with hepatocyte injury presented with hepatocyte ballooning degeneration and focal necrosis, patients with cholestasis type exhibited with cholestasis and bile duct injury, and patients with mixed type demonstrated with hepatocyte injury and cholestasis; after one to three week treatment, 55 patients (94.8%)with hepatocyte injury, 15 patients (75.0%)with cholestasis type and 28 patients (80.0%)with mixed type recovered. Conclusion The clinical manifestations of patients with DILI are usually nonspecific, and hepatocyte type is the most common clinical classification. The main pathological characteristics of liver include inflammatory cell infiltration, hepatocyte swelling and necrosis. After discontinuing suspected drugs and active liver protection treatment, there is a good prognosis in most patients with DILI.

Key words: Drug-induced liver injury, Clinical feature, Pathological manifestation, Prognosis